Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike heart failure with reduced ejection fraction (HFrEF), which has numerous proven therapies, HFpEF has historically lacked effective treatments. This syndrome disproportionately affects older adults, women, and those with obesity—a patient population that has been underrepresented in cardiovascular trials. The obesity-HFpEF phenotype is increasingly recognized as a distinct entity characterized by excessive epicardial and systemic adiposity, volume overload, systemic inflammation, and impaired cardiac reserve. Weight gain exacerbates symptoms, while weight loss through bariatric surgery has shown dramatic improvements in HFpEF parameters.…
Author: FWA
Clinical Context Type 2 diabetes ultimately results from beta-cell failure—the inability of pancreatic beta cells to produce sufficient insulin to overcome insulin resistance. While insulin resistance initiates the disease process, beta-cell dysfunction determines progression from prediabetes to overt diabetes. Understanding the molecular regulators of beta-cell function could identify biomarkers for disease progression and potential therapeutic targets. Gremlin 2 (Grem2) is a secreted protein that antagonizes bone morphogenetic proteins (BMPs). While originally studied in developmental biology and bone metabolism, emerging evidence suggests Grem2 plays roles in metabolic regulation. BMP signaling affects insulin sensitivity, adipose tissue function, and potentially beta-cell biology. As…
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg subcutaneous injection weekly significantly reduced NT-proBNP by 18% (treatment ratio 0.82, P=0.0002) and improved health status, with greater KCCQ benefits (up to 11.9 points) in higher baseline NT-proBNP tertiles compared to matching placebo, with consistent weight loss across NT-proBNP tertiles and no significant safety concerns. PICO Description Population 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30) from STEP-HFpEF trials. Intervention Semaglutide 2.4 mg subcutaneous weekly, titrated over 16 weeks. Comparison Matching placebo injection weekly. Outcome NT-proBNP reduced 18%. KCCQ…
Clinical Context Polycystic ovary syndrome (PCOS) affects 6-12% of reproductive-age women and extends far beyond reproductive concerns. It’s increasingly recognized as a metabolic syndrome with insulin resistance, dyslipidemia, oxidative stress, and chronic low-grade inflammation at its core. Women with PCOS have elevated cardiovascular risk, increased diabetes incidence, and accelerated atherosclerosis—making metabolic management essential alongside reproductive care. Standard PCOS treatment includes lifestyle modification, metformin for insulin resistance, and symptom-specific management (oral contraceptives for hyperandrogenism, ovulation induction for infertility). However, many women seek complementary approaches, either as adjuncts to conventional treatment or as alternatives when standard therapies are insufficient or cause side…
Summary: In adults with chronic hypoparathyroidism requiring conventional therapy with calcium and active vitamin D, TransCon PTH (palopegteriparatide) once daily via subcutaneous injection achieved normal serum calcium AND independence from conventional therapy in 81% at week 52; 95% achieved independence from calcium/vitamin D supplementation; urinary calcium decreased from 376 to 195 mg/day compared to placebo with continuation of conventional therapy, with mild to moderate adverse events and no trial discontinuations. PICO Description Population Adults with chronic hypoparathyroidism requiring conventional calcium and vitamin D therapy. Intervention TransCon PTH (palopegteriparatide) once daily subcutaneous injection, titrated to target calcium. Comparison Placebo injection with…
Clinical Context The concept of type 2 diabetes “remission”—achieving normal glycemia without diabetes medications—has been revolutionized by intensive dietary intervention studies, particularly the UK DiRECT trial. DiRECT demonstrated that a structured low-calorie diet program could achieve diabetes remission in nearly half of participants, with remission rates correlating strongly with weight loss. However, DiRECT enrolled predominantly Caucasian participants, raising questions about generalizability to other populations. Asian populations, including Chinese individuals, develop type 2 diabetes at lower BMI thresholds than Caucasians, with more prominent beta-cell dysfunction relative to insulin resistance. Whether the “remission through weight loss” paradigm translates equivalently to populations with…
Summary: In adults with chronic kidney disease (eGFR ≥25, UACR 30-3,500 mg/g) and overweight/obesity (BMI ≥27) without diabetes, semaglutide 2.4 mg subcutaneous injection weekly for 24 weeks reduced UACR by 52.1% (95% CI -65.5% to -33.4%, P<0.0001) compared to matching placebo injection weekly, with GI adverse events more common but consistent with known GLP-1 RA safety profile. PICO Description Population Adults with CKD (eGFR ≥25, UACR 30-3,500) and BMI ≥27 without diabetes. Intervention Semaglutide 2.4 mg subcutaneous weekly for 24 weeks, titrated per protocol. Comparison Matching placebo injection weekly for 24 weeks. Outcome UACR reduced 52.1% vs placebo. GI adverse…
Clinical Context Diabetic foot ulcers (DFUs) are traditionally managed with wound care, offloading, infection control, and vascular optimization. Exercise is typically not emphasized during active DFU treatment—and may even be restricted due to concerns about offloading compliance, wound trauma, and energy expenditure diversion from healing. However, this paradigm may miss opportunities: exercise improves glycemic control, enhances circulation, reduces inflammation, and promotes tissue repair—all potentially beneficial for wound healing. The challenge is designing exercise that doesn’t compromise the healing foot. Lower limb resistance training, when appropriately structured to avoid direct pressure on the wound and maintain offloading principles, could provide metabolic…
Clinical Context Radioactive iodine (RAI) ablation is a cornerstone of differentiated thyroid cancer (DTC) management following total thyroidectomy. Effective RAI uptake by thyroid tissue (remnant or metastatic) requires elevated TSH levels to stimulate iodine transporters. Traditionally, this was achieved through thyroid hormone withdrawal (THW)—stopping levothyroxine for 3-4 weeks to induce hypothyroidism and raise endogenous TSH. While effective, THW causes significant morbidity: fatigue, cognitive impairment, depression, cold intolerance, weight gain, and reduced quality of life. Recombinant human TSH (rhTSH, Thyrogen) offers an alternative: exogenous TSH stimulation while maintaining euthyroidism on levothyroxine. Patients avoid hypothyroid symptoms entirely. However, questions remained about whether…
Clinical Context The GLP-1 receptor agonist class has transformed type 2 diabetes management, with semaglutide emerging as a particularly effective agent for both glycemic control and weight loss. However, the development of tirzepatide—a novel dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors—raised the question of whether engaging two incretin pathways could outperform single-target GLP-1 agonism. SURPASS-2 represents the definitive head-to-head comparison: tirzepatide versus semaglutide 1.0 mg (the maximum approved dose for type 2 diabetes) in a Phase 3 randomized controlled trial. While the primary results showed tirzepatide’s superiority for HbA1c reduction, this analysis digs deeper into the…